title: Post-translational processing of purified human K-ras in Xenopus oocytes.
abstract: Membrane localization of ras p21 involves a complex series of post-translational processing events, including S-farnesylation of Cys-186, removal of three carboxyl-terminal amino acid residues, and methylation of the carboxyl-terminal farnesylcysteine residue. Palmitoylation of cysteine residues within the hypervariable region (amino acids 165-185) is also required for membrane localization of mammalian H-, N-, and K-ras(A). For K-ras(B), which contains no cysteine residues within the hypervariable region, a polybasic domain substitutes for palmitoylation as a second signal for plasma membrane targeting. In order to investigate the localization of K-ras(B) to the plasma membrane, we purified wild-type and mutant human K-ras(B) proteins from strains of E. coli harboring bacterial expression plasmids and injected them into Xenopus laevis oocytes. Our results show that wild-type and activated K-ras(B) proteins can be post-translationally modified and can induce meiotic maturation in Xenopus oocytes. A mutation at Cys-186 (Cys to Gly) abolished the ability of activated K-ras(B) to induce meiosis. Deprivation of isoprenyl precursors by the addition of lovastatin, a drug that blocks the synthesis of mevalonate, also abolished the ability of activated K-ras(B) to induce meiosis, although this inhibition could be overcome by the addition of exogenous mevalonate. Lovastatin did not block meiotic maturation induced by microinjection of purified mos protein, a component of the cytostatic factor that arrests Xenopus oocytes at the first meiotic prophase. These results indicate that post-translational isoprenylation of K-ras(B) is essential for plasma membrane targeting and induction of meiotic maturation in Xenopus oocytes and that further isoprenyl modification of proteins downstream from mos signal transduction is not essential for this process.
authors.affiliation: Oncology and Immunology Research Department, Medical Research Division, Lederle Laboratories, Pearl River, New York 10965, USA.
authors.forename: J B
authors.initials: JB
authors.lastname: Kaplan
authors.forename: P M
authors.initials: PM
authors.lastname: Sass
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D011905:Genes, ras / Q000502:physiology*; D006801:Humans; D008148:Lovastatin / Q000494:pharmacology; D008540:Meiosis / Q000187:drug effects; D008845:Microinjections; D009154:Mutation; D017232:Oncogene Proteins v-mos / Q000378:metabolism; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism*; D017368:Protein Prenylation; D011499:Protein Processing, Post-Translational; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism*; D014982:Xenopus laevis
chemical_list: D000970:Antineoplastic Agents; D017232:Oncogene Proteins v-mos; D008148:Lovastatin; D016283:Proto-Oncogene Proteins p21(ras)